Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allakos Inc (ALLK)
NASDAQ:ALLK
Allakos (ALLK) Stock Price & Analysis
209 Followers
ALLK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.00 - $5.64
Previous Close$1.06
Volume336.72K
Average Volume (3M)841.13K
Market Cap
$93.15M
Enterprise Value-$39.43M
Total Cash (Recent Filing)$170.79M
Total Debt (Recent Filing)$38.22M
Price to Earnings (P/E)-0.5
Beta1.05
Next Earnings
May 07, 2024EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding87,873,995
10 Day Avg. Volume458,878
30 Day Avg. Volume841,134
Standard Deviation0.31
R-Squared0.02
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.56
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.21
Forecast
1Y Price Target
$4.00Price Target Upside277.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Allakos News
Bulls Say, Bears Say
Bulls Say
Analyst OpinionAnalyst reiterates a strong Market Outperform rating with a robust price target, reflecting a high level of confidence in the stock's potential upside.
Financial StabilityThe company ended the year with significant cash reserves, which management expects to sustain operations well into the future, underpinning the company's financial stability.
Product DevelopmentAllakos is advancing a next generation mast cell inhibitor, AK006, which is entering clinical trials and showing promise as a more potent alternative to existing therapies.
Bears Say
Company RestructuringALLK will cease further lire development and reduce its workforce by approximately 50% to prioritize its second program, AK006.
Drug Development FailureAllakos's randomized, double-blind, placebo-controlled Phase 2 studies testing lirentelimab for atopic dermatitis and chronic spontaneous urticaria failed to meet their primary endpoints.
Financial Performance4Q23 Operating Expenses of $65M were above consensus estimates, driven by higher-than-anticipated R&D costs.
---
Ownership Overview
69.78% Insiders
16.95% Mutual Funds
7.56% Other Institutional Investors
5.71% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLK FAQ
What was Allakos Inc’s price range in the past 12 months?
Allakos Inc lowest stock price was $1.00 and its highest was $5.64 in the past 12 months.
What is Allakos Inc’s market cap?
Currently, no data Available
When is Allakos Inc’s upcoming earnings report date?
Allakos Inc’s upcoming earnings report date is May 07, 2024 which is in 18 days.
How were Allakos Inc’s earnings last quarter?
Allakos Inc released its earnings results on Mar 14, 2024. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.474 by -$0.236.
Is Allakos Inc overvalued?
According to Wall Street analysts Allakos Inc’s price is currently Undervalued.
Does Allakos Inc pay dividends?
Allakos Inc does not currently pay dividends.
What is Allakos Inc’s EPS estimate?
Allakos Inc’s EPS estimate is -$0.46.
How many shares outstanding does Allakos Inc have?
Allakos Inc has 87,873,990 shares outstanding.
What happened to Allakos Inc’s price movement after its last earnings report?
Allakos Inc reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.474. Following the earnings report the stock price went up 0.769%.
Which hedge fund is a major shareholder of Allakos Inc?
Among the largest hedge funds holding Allakos Inc’s share is Blackstone Inc.. It holds Allakos Inc’s shares valued at 11M.
---
Allakos Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (277.36% Upside)
$4.00 (277.36% Upside)
Blogger Sentiment
Bearish
ALLK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 122.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.08%
12-Months-Change
Fundamentals
Return on Equity
-77.50%
Trailing 12-Months
Asset Growth
-36.96%
Trailing 12-Months
Company Description
Allakos Inc
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.
---
ALLK Stock 12 Months Forecast
Average Price Target
$4.00
▲(277.36% Upside)
Technical Analysis
Best Analysts Covering ALLK
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+49.93%
upgraded a buy rating 4 months ago
Copying Tim Lugo's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +49.93% per trade.
---